Clearbridge Health

What Clearbridge Health does

Clearbridge Health Limited is an integrated healthcare and medical services group headquartered in Singapore (37 Jalan Pemimpin, #08-05 Mapex) and listed on the SGX Catalist Board (ticker 1H3) since December 2017, formerly known as Clearbridge Accelerator Pte. Ltd. The company operates two business segments — Medical Services and Healthcare Systems — organised around precision medicine, defined as personalised disease treatment and prevention accounting for individual variability in genes, environment, and lifestyle. Its delivery combines an owned network of medical centres and clinics (under the Clearbridge Medical Group brand in Singapore, Hong Kong, China, and the Philippines) with partnerships to globally-accredited laboratories and specialised medical institutions across Asia.

Its core services include general medical care (health screenings, vaccinations), diagnostic imaging (X-ray, CT, MRI, mammography, ultrasound), and a broad specialists portfolio spanning aesthetics, dental and orthodontics, dermatology, diagnostic radiology, infectious diseases, internal medicine, medical oncology, obstetrics and gynaecology, and renal medicine. Distribution is augmented by channel partnerships — notably exclusive Asia distribution rights for NanoString's Prosigna Breast Cancer Prognostic Gene Signature Assay, collaborations with A*STAR's Genome Institute of Singapore and Australia's Genome.One for personal health genomics, and an exclusive China partnership with Agen Lab — plus legacy channel deals with MILS International across 11 Asian countries. In November 2025, the group launched Cell Entrust Bio Co. Ltd. in Hong Kong, billed as Hong Kong's first biobank focused exclusively on adult immune cell banking, targeting Hong Kong and Southeast Asia.

Revenue is generated by fee-for-service medical procedures at owned clinics, specialist consultations, diagnostic imaging, vaccination programmes, and royalty/distribution income from partner-lab arrangements; the company has progressively divested non-core laboratory assets (Singapore Clinical Lab in March 2020; Clearbridge Medical Asia / SAM Laboratory in October 2022) to refocus on clinic operations and, increasingly, consumer-facing precision medicine products. The group serves two primary segments: individual patients seeking primary and specialist healthcare across Asia, and medical institutions/laboratories requiring precision-medicine-enabled diagnostic infrastructure. With 11–50 employees, a multi-jurisdictional Asian footprint, and a July 2026 leadership transition (new Group CEO Ong Choon Yi and reconstituted board), the company is in an active strategic repositioning phase.

Name

Clearbridge Health

Legal name

Clearbridge Health Limited

Website

https://clearbridgehealth.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Clearbridge Health Limited is a Singapore-headquartered, SGX Catalist-listed integrated healthcare and medical services group operating clinics and specialist centres across Singapore, Hong Kong, China, and the Philippines, delivering precision medicine through general practice, imaging, specialist services, and an adult immune cell biobank (Cell Entrust) in Hong Kong.

Ownership category

akta.pro rank

Product category

Precision Medicine Healthcare Services

NAICS

Ambulatory Health Care Services (621), Medical Laboratories (621511), Blood and Organ Banks (621991), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro primary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Precision medicine services
• Medical diagnostics imaging
• Specialist healthcare clinics
• Clinical laboratory testing
• Immune cell banking

Headquarters

HQ city

Midview City

HQ country

Singapore

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Medical Services Revenue: Revenue generated from operating a network of medical centers and clinics providing general medical services, specialist services, imaging services, and vaccinations across Asia.
2. Healthcare Systems Revenue: Revenue from partnerships with medical institutions and laboratory facilities, extending healthcare ecosystem reach across Asia.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Clearbridge Health operates an integrated healthcare and medical services group across Asia with two business segments: Medical Services (general medical services, health screenings, imaging diagnostics including X-ray, CT, MRI, mammography, ultrasound, vaccinations, and specialist services in aesthetics, dental, dermatology, oncology, and other disciplines) delivered through the Clearbridge Medical Group clinic network; and Healthcare Systems (partnerships with medical institutions and globally-accredited laboratories for precision medicine delivery, including CAP-accredited laboratory testing and the Prosigna Breast Cancer Prognostic Gene Signature Assay). In November 2025 the group launched Cell Entrust, Hong Kong's first biobank focused exclusively on adult immune cell banking.

Product overview

Clearbridge Health Limited is an integrated healthcare and medical services group operating two business segments: Medical Services and Healthcare Systems. The company's Medical Services segment provides primary healthcare through a network of General Practitioner services, encompassing general health screenings, vaccinations, and imaging diagnostics (X-ray, CT, MRI, mammography, ultrasound). The Specialists Services division offers medical specialist care across aesthetics, dental, dermatology, oncology, and other disciplines. The company operates across Asia through its Clearbridge Medical Group brand with locations in Singapore, Hong Kong, China, and the Philippines. In November 2025, the company launched Cell Entrust, a new adult immune cell banking business in Hong Kong targeting Southeast Asia markets.

Differentiator

Problem solved

Functional benefit

Brands

• Clearbridge Medical Group: Network of medical centres and clinics across Asia providing general medical services, specialist services, and imaging services
• Cell Entrust
• Clearbridge Medical Philippines
• Clearbridge Medical Hong Kong (明確醫療中心)

Products and services

• Medical Services Comprehensive healthcare service delivery through Clearbridge Medical Group clinics across Asia, encompassing general medical services, imaging services, specialist services, and vaccinations for individual patients.
• General Medical Services Primary healthcare services including general health screenings for diabetes, high blood pressure, and high cholesterol, plus vaccination services covering various diseases. Provided to individual patients at Clearbridge clinics.
• Imaging Services Diagnostic and preventative imaging services including General X-ray, CT Scan, Dental Cone Beam CT Scan, Mammography, MRI, and Ultrasound for early disease detection and medical investigation. Provided to individual patients at Clearbridge clinics.
• Vaccinations Immunisation services covering Hepatitis B, Rotavirus, DTaP, Hib, Influenza, MMR, Varicella, Hepatitis A, HPV, Meningococcal, Pneumococcal, and Shingles vaccines, offered to individual patients at Clearbridge clinics.
• Specialists Services Medical specialist services spanning aesthetics, dental and orthodontics, dermatology, diagnostic radiology, infectious diseases, internal medicine, medical oncology, obstetrics and gynaecology, and renal medicine, delivered by medical specialists across various locations in Asia.
• Cell Entrust Adult Immune Cell Banking Adult immune cell banking service operated by Cell Entrust Bio Co. Ltd., enabling individuals in Hong Kong and Southeast Asia to store their immune cells at their healthiest for future personalised and precision medicine applications.

Quantifiable outcome

• Record revenue of S$36.26 Million achieved in FY2020, demonstrating significant turnaround
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core.

• Cell Entrust Bio Co. Ltd.coreChannel Partner/ Reseller/ Distributor · 3 November 2025Launch of Cell Entrust Bio Co. Ltd. in Hong Kong, Hong Kong's first biobank focused exclusively on adult immune cell banking. Clearbridge Health launches this subsidiary for immune cell banking services targeting Southeast Asia and Hong Kong.
• Dental Focus (Singapore)coreChannel Partner/ Reseller/ Distributor · 24 May 2019Acquisition of majority stake in 9 Dental Focus clinics in Singapore, expanding dental and orthodontics services.
• PT Indo Genesis Medika (Indonesia)coreChannel Partner/ Reseller/ Distributor · 3 April 2019Proposed investment and subsequent acquisition of shares in PT Indo Genesis Medika (IGM Labs), completing subscription of redeemable exchangeable bond for Indonesia expansion.
• Agen LabcoreChannel Partner/ Reseller/ Distributor · 23 July 2018Exclusive partnership for China distribution and test development. Clearbridge signs exclusive partnership with Agen Lab for distribution and development of tests in China.
• Genome.One (Australia)coreTechnology or Integration · 26 June 2018Partnership to offer personal health genomics programme. Clearbridge collaborates with Genome.One to bring personal health genomics services to patients in Asia.
• Olivia Newton-John Cancer Research InstitutecoreStrategic or Co-development Partner · 27 April 2018Ongoing collaboration in cancer research. Clearbridge continues collaboration with the institute for cancer research initiatives.
• A*STAR's Genome Institute of Singapore (GIS)coreStrategic or Co-development Partner · 25 April 2018Partnership to offer Prosigna Breast Cancer Test in Singapore. Clearbridge Health partners with A*STAR's GIS for this diagnostic service.
• PT Tirta Medika Jaya (Indonesia)coreChannel Partner/ Reseller/ Distributor · 23 April 2018Completion of acquisition of shares in PT Tirta Medika Jaya, expanding laboratory testing services to Indonesia.
• Medic Laser Pte Ltd and Medic Surgical Pte LtdcoreChannel Partner/ Reseller/ Distributor · 2 April 2018Completion of acquisition of shares in Medic Laser Pte Ltd and Medic Surgical Pte Ltd, medical aesthetics clinic operators.
• MILS InternationalcoreChannel Partner/ Reseller/ Distributor · 23 January 2018Clearbridge Health appointed as exclusive distributor for MILS International in 11 countries, expanding distribution network across Asia.
• Marzan Health Care Inc. (Philippines)coreChannel Partner/ Reseller/ Distributor · 17 January 2018Proposed acquisition of shares in Marzan Health Care Inc. for entry into the Philippines market through medical centre operations.
• NanoString TechnologiescoreTechnology or Integration · 20 November 2017Partnership to provide Prosigna Breast Cancer Prognostic Gene Signature Assay in Asia. Clearbridge Health serves as the exclusive distributor for the Prosigna test in specified Asian markets.
• Clearbridge Medical Philippines (Joint Venture)coreChannel Partner/ Reseller/ DistributorClearbridge Medical Philippines provides medical centre services in the Philippines with Dr. Rainier Nery Mozo serving as Medical Director.
• Shanghai Kai Zhun Health Management Co. LtdcoreChannel Partner/ Reseller/ DistributorChina operations partner providing health management services in Shanghai, China.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cordlife Group: Singapore-listed cord blood and tissue banking operator. Most directly comparable to Clearbridge's Cell Entrust adult immune cell banking business; notably, former Clearbridge CEO Jeremy Yee previously led Cordlife from 2011 to 2016.
• Raffles Medical Group: Singapore-listed integrated private healthcare provider operating a network of medical clinics, specialist centres, and hospitals across Asia. Most directly comparable regional peer in terms of multi-country GP/specialist clinic model and SGX listing, though at significantly larger scale.
• TalkMed Group: SGX-listed specialist oncology and medical services provider offering medical oncology, palliative care, and stem cell transplant services. Comparable in the oncology specialist and precision medicine positioning Clearbridge pursues.
• Singapore Medical Group: SGX-listed specialist healthcare provider with a network of specialist clinics across aesthetics, oncology, ophthalmology, and diagnostics. Comparable in specialist services focus and precision diagnostics positioning.
• Healthway Medical Corporation: Singapore-listed primary care and specialist clinic network with operations across the region. Highly comparable in clinic-led, multi-specialty outpatient model and Asian footprint.
• Q & M Dental Group: Singapore-listed dental clinic group with regional footprint. Comparable to Clearbridge's Dental Focus (9-clinic) dental vertical and shares the multi-country Asian clinic roll-up model.

Emerging players

• Asia Genomics: Singapore-based precision medicine and genomics diagnostics provider. Comparable in the molecular diagnostics and precision medicine delivery layer Clearbridge targets through its Prosigna partnership.
• Life Corporation Limited: Australia-listed healthcare group (formerly Cordlife Limited) operating stem cell and tissue banking businesses. Comparable to Clearbridge's Cell Entrust in the cell-banking category and shares historical leadership lineage with Clearbridge's ex-CEO.

Broad incumbents

• IHH Healthcare: Largest premium Asian hospital operator (Mount Elizabeth, Gleneagles, Pantai, Acibadem brands) listed in Malaysia and dual-listed in SGX. Overlaps with Clearbridge's premium healthcare delivery across Asia but at vastly larger scale and focused on inpatient rather than outpatient clinics.

Regional players

• KPJ Healthcare: Malaysia-listed private hospital network across Southeast Asia. Comparable as a regional multi-country private healthcare operator serving cross-border patients, though inpatient-focused rather than clinic-led.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/C_HealthLimited
• LinkedInlinkedin.com/company/clearbridgehealth

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clearbridge Health